Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kids with rare MMA: B12 shot trial aims to tame toxic acids

NCT ID NCT07163364

First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 26 times

Summary

This study tests a vitamin B12 injection (hydroxocobalamin) in 20 children aged 6 months to 18 years with a rare genetic condition called methylmalonic acidemia (MMA) with high homocysteine. The goal is to see if the injection can normalize harmful acid levels in the blood or urine. Participants receive the drug openly, and researchers monitor safety and effectiveness over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHYLMALONIC ACIDEMIA (MMA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.